PE20211768A1 - Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso - Google Patents
Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su usoInfo
- Publication number
- PE20211768A1 PE20211768A1 PE2021000757A PE2021000757A PE20211768A1 PE 20211768 A1 PE20211768 A1 PE 20211768A1 PE 2021000757 A PE2021000757 A PE 2021000757A PE 2021000757 A PE2021000757 A PE 2021000757A PE 20211768 A1 PE20211768 A1 PE 20211768A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- antagonists
- substituted
- triazolo
- quinazoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a un compuesto de formula estructural (I), o una sal farmaceuticamente aceptable del mismo, en donde: R1 es F, Cl, alquilo C1-C6 y O(alquilo C1-C6); R2 es H, F, Cl, alquilo C1-C6 y O(alquilo C1-C6); el anillo A es i), ii), iii), entre otros; R3 es pirazolilo, triazolilo y piridinilo sustituidos con grupos R3A, donde R3A es alquilo C1-C6, O(alquilo C1-C6), entre otros; RA1 es H y alquilo C1-C4; RA2 y RA3 son H, F y alquilo C1-C4. Son compuestos preferidos los compuestos a), b), c), entre otros. Tambien se refiere a una composicion farmaceutica. Dichos compuestos son derivados de amino triazolo quinazolina 9-sustituidos y antagonistas de los receptores A2a y/o A2b de adenosina, siendo utiles en el tratamiento del cancer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862774077P | 2018-11-30 | 2018-11-30 | |
PCT/US2019/063136 WO2020112700A1 (en) | 2018-11-30 | 2019-11-26 | 9-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20211768A1 true PE20211768A1 (es) | 2021-09-07 |
Family
ID=69005832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2021000757A PE20211768A1 (es) | 2018-11-30 | 2019-11-26 | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso |
Country Status (25)
Country | Link |
---|---|
US (2) | US11312719B2 (es) |
EP (1) | EP3886988A1 (es) |
JP (1) | JP7241871B2 (es) |
KR (1) | KR102653800B1 (es) |
CN (1) | CN113329791A (es) |
AR (1) | AR117164A1 (es) |
AU (1) | AU2019385905B2 (es) |
BR (1) | BR112021010427B1 (es) |
CA (1) | CA3120862C (es) |
CL (1) | CL2021001406A1 (es) |
CO (1) | CO2021006888A2 (es) |
CR (1) | CR20210271A (es) |
DO (1) | DOP2021000104A (es) |
EA (1) | EA202191498A1 (es) |
EC (1) | ECSP21036982A (es) |
IL (1) | IL283334A (es) |
JO (2) | JOP20210117A1 (es) |
MA (1) | MA54298A (es) |
MX (1) | MX2021006329A (es) |
NI (1) | NI202100043A (es) |
PE (1) | PE20211768A1 (es) |
PH (1) | PH12021551196A1 (es) |
SG (1) | SG11202105180PA (es) |
TW (1) | TW202039496A (es) |
WO (1) | WO2020112700A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
WO2017210134A1 (en) | 2016-05-31 | 2017-12-07 | Board Of Regents, University Of Texas System | Heterocyclic inhibitors of ptpn11 |
MX2020011528A (es) | 2018-05-02 | 2021-02-09 | Navire Pharma Inc | Inhibidores heterociclicos sustituidos de ptpn11. |
EP4356973A2 (en) | 2018-08-10 | 2024-04-24 | Navire Pharma, Inc. | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
WO2023158626A1 (en) * | 2022-02-16 | 2023-08-24 | Merck Sharp & Dohme Llc | Adenosine receptor antagonists, pharmaceutical compositions and their use thereof |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957766A (en) | 1970-06-19 | 1976-05-18 | Boehringer Mannheim G.M.B.H. | Novel nitrofuran compounds and pharmaceutical compositions |
DE2109577A1 (de) | 1971-03-01 | 1972-09-14 | Boehringer Mannheim Gmbh | Antimikrobiell wirksame Nitrofuran Derivate und Verfahren zur Herstellung derselben |
US4713383A (en) | 1984-10-01 | 1987-12-15 | Ciba-Geigy Corporation | Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses |
GB9524395D0 (en) | 1995-11-29 | 1996-01-31 | Nickerson Biocem Ltd | Promoters |
US6759759B2 (en) | 2000-08-29 | 2004-07-06 | Tamagawa Seiki Kabushiki Kaisha | Rotary contactless connector and non-rotary contactless connector |
KR100687954B1 (ko) | 2001-10-15 | 2007-02-27 | 쉐링 코포레이션 | 아데노신 A2a 수용체 길항제로서의이미다조(4,3-e)-1,2,4-트리아졸로(1,5-c) 피리미딘 |
ATE453647T1 (de) | 2001-11-30 | 2010-01-15 | Schering Corp | Adenosin a2a rezeptor antagonisten |
TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
ATE481985T1 (de) | 2002-07-03 | 2010-10-15 | Ono Pharmaceutical Co | Immunpotenzierende zusammensetzungen |
JPWO2004029056A1 (ja) | 2002-09-24 | 2006-01-26 | 協和醗酵工業株式会社 | [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体 |
CA2508660C (en) | 2002-12-23 | 2013-08-20 | Wyeth | Antibodies against pd-1 and uses therefor |
EP1591527B1 (en) | 2003-01-23 | 2015-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
EP1615931A1 (en) | 2003-04-09 | 2006-01-18 | Biogen Idec MA Inc. | Triazolopyrazines and methods of making and using the same |
PL1678182T3 (pl) | 2003-10-28 | 2007-05-31 | Schering Corp | Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn |
ES2342082T3 (es) | 2004-04-21 | 2010-07-01 | Schering Corporation | Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina. |
US7472383B2 (en) | 2004-08-13 | 2008-12-30 | Sun Microsystems, Inc. | System and method for providing exceptional flow control in protected code through memory layers |
MX2007007604A (es) | 2004-12-21 | 2007-08-02 | Schering Corp | Antagonistas del receptor de pirazolo[1,5-a]pirimidina adenosina a2a. |
SI2439273T1 (sl) | 2005-05-09 | 2019-05-31 | Ono Pharmaceutical Co., Ltd. | Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki |
CN101248089A (zh) | 2005-07-01 | 2008-08-20 | 米德列斯公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
WO2007035542A1 (en) | 2005-09-19 | 2007-03-29 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
CN101506215A (zh) | 2006-06-26 | 2009-08-12 | 先灵公司 | 腺苷A2a受体拮抗剂 |
KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 pd-1에 대한 항체 |
PE20091101A1 (es) | 2007-12-18 | 2009-07-26 | Pharminox Ltd | AMIDAS DE ACIDO 3-SUBSTITUIDO-4-OXO-3,4-DIHIDRO-IMIDAZO[5,1-d] [1,2,3,5-TETRACINA-8-CARBOXILICO Y SU EMPLEO |
WO2009111442A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
JP2012510429A (ja) | 2008-08-25 | 2012-05-10 | アンプリミューン、インコーポレーテッド | Pd−1アンタゴニストおよびその使用方法 |
SI2342226T1 (sl) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe |
UA109108C2 (uk) | 2008-12-09 | 2015-07-27 | Дженентек, Інк. | Антитіло до pd-l1 та його застосування для посилення функції t-клітин |
US8435994B2 (en) | 2009-11-16 | 2013-05-07 | Merck Sharp & Dohme Corp. | Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
CA2843595C (en) | 2011-08-01 | 2022-10-18 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
US9495379B2 (en) | 2012-10-08 | 2016-11-15 | Veritas Technologies Llc | Locality aware, two-level fingerprint caching |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2015027431A1 (en) | 2013-08-29 | 2015-03-05 | Merck Sharp & Dohme Corp. | 2,2-difluorodioxolo a2a receptor antagonists |
EP3220910B1 (en) | 2014-11-18 | 2020-01-15 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
WO2016089796A1 (en) | 2014-12-04 | 2016-06-09 | Merck Sharp & Dohme Corp. | Formulation inhibiting effects of low acid environment |
EP3253390B1 (en) | 2015-02-06 | 2022-04-13 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as a2a antagonist |
EP3307067B1 (en) | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
WO2016209787A1 (en) | 2015-06-26 | 2016-12-29 | Merck Sharp & Dohme Corp. | Sustained release formulation and tablets prepared therefrom |
WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
PL3570844T3 (pl) * | 2017-01-20 | 2024-02-26 | Arcus Biosciences, Inc. | Azolopirymidyna do leczenia zaburzeń związanych z nowotworami |
WO2019118313A1 (en) | 2017-12-13 | 2019-06-20 | Merck Sharp & Dohme Corp. | Imidazo [1,2-c] quinazolin-5-amine compounds with a2a antagonist properties |
MX2020012376A (es) | 2018-05-18 | 2021-03-09 | Incyte Corp | Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b. |
EP3883575A4 (en) | 2018-11-20 | 2022-06-15 | Merck Sharp & Dohme Corp. | SUBSTITUTE AMINO-TRIAZOLOPYRIMIDINE AND AMINO-TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITIONS AND THEIR USE |
WO2020106560A1 (en) | 2018-11-20 | 2020-05-28 | Merck Sharp & Dohme Corp. | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
AU2019388872A1 (en) | 2018-11-30 | 2021-05-27 | Merck Sharp & Dohme Llc | 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives as adenosine receptor antagonists, pharmaceutical compositions and their use |
-
2019
- 2019-11-26 US US16/695,367 patent/US11312719B2/en active Active
- 2019-11-26 MX MX2021006329A patent/MX2021006329A/es unknown
- 2019-11-26 JO JOP/2021/0117A patent/JOP20210117A1/ar unknown
- 2019-11-26 JO JOP/2021/0116A patent/JOP20210116A1/ar unknown
- 2019-11-26 CA CA3120862A patent/CA3120862C/en active Active
- 2019-11-26 CR CR20210271A patent/CR20210271A/es unknown
- 2019-11-26 AR ARP190103450A patent/AR117164A1/es unknown
- 2019-11-26 BR BR112021010427-5A patent/BR112021010427B1/pt active IP Right Grant
- 2019-11-26 KR KR1020217019802A patent/KR102653800B1/ko active IP Right Grant
- 2019-11-26 EA EA202191498A patent/EA202191498A1/ru unknown
- 2019-11-26 SG SG11202105180PA patent/SG11202105180PA/en unknown
- 2019-11-26 PE PE2021000757A patent/PE20211768A1/es unknown
- 2019-11-26 TW TW108142874A patent/TW202039496A/zh unknown
- 2019-11-26 JP JP2021530114A patent/JP7241871B2/ja active Active
- 2019-11-26 EP EP19827893.9A patent/EP3886988A1/en active Pending
- 2019-11-26 WO PCT/US2019/063136 patent/WO2020112700A1/en active Application Filing
- 2019-11-26 AU AU2019385905A patent/AU2019385905B2/en active Active
- 2019-11-26 MA MA054298A patent/MA54298A/fr unknown
- 2019-11-26 CN CN201980090487.8A patent/CN113329791A/zh active Pending
-
2021
- 2021-05-20 IL IL283334A patent/IL283334A/en unknown
- 2021-05-24 NI NI202100043A patent/NI202100043A/es unknown
- 2021-05-25 EC ECSENADI202136982A patent/ECSP21036982A/es unknown
- 2021-05-25 PH PH12021551196A patent/PH12021551196A1/en unknown
- 2021-05-26 CO CONC2021/0006888A patent/CO2021006888A2/es unknown
- 2021-05-27 DO DO2021000104A patent/DOP2021000104A/es unknown
- 2021-05-27 CL CL2021001406A patent/CL2021001406A1/es unknown
-
2022
- 2022-03-31 US US17/657,515 patent/US20220220117A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JOP20210116A1 (ar) | 2023-01-30 |
JOP20210117A1 (ar) | 2023-01-30 |
US20210107904A1 (en) | 2021-04-15 |
MX2021006329A (es) | 2021-08-11 |
KR102653800B1 (ko) | 2024-04-01 |
WO2020112700A1 (en) | 2020-06-04 |
MA54298A (fr) | 2022-03-09 |
NI202100043A (es) | 2021-08-13 |
CA3120862C (en) | 2024-05-07 |
EP3886988A1 (en) | 2021-10-06 |
SG11202105180PA (en) | 2021-06-29 |
US20220220117A1 (en) | 2022-07-14 |
AU2019385905B2 (en) | 2023-01-12 |
ECSP21036982A (es) | 2021-06-30 |
AU2019385905A1 (en) | 2021-06-03 |
CN113329791A (zh) | 2021-08-31 |
BR112021010427A2 (pt) | 2021-08-17 |
AR117164A1 (es) | 2021-07-14 |
BR112021010427B1 (pt) | 2022-09-27 |
DOP2021000104A (es) | 2021-07-30 |
IL283334A (en) | 2021-07-29 |
CL2021001406A1 (es) | 2021-11-12 |
US11312719B2 (en) | 2022-04-26 |
CR20210271A (es) | 2021-07-14 |
TW202039496A (zh) | 2020-11-01 |
PH12021551196A1 (en) | 2021-11-29 |
JP2022511441A (ja) | 2022-01-31 |
CO2021006888A2 (es) | 2021-06-10 |
JP7241871B2 (ja) | 2023-03-17 |
EA202191498A1 (ru) | 2021-08-20 |
KR20210096184A (ko) | 2021-08-04 |
CA3120862A1 (en) | 2020-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20211768A1 (es) | Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmaceuticas y su uso | |
NI201800033A (es) | Derivados de 8-[6-[3-(amino)propoxi]-3piridil]-1-isopropil-imidazo[4, 5-c]quinolin -2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer. | |
CU20190010A7 (es) | PIRIDO[2,3-d]PIRIMIDIN-7(8H)-ONAS 6-FLUOROALQUIL-2-(ALQUILSULFONILPIPERIDIN-4-IL)AMINO SUSTITUIDAS | |
DOP2019000104A (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer | |
PE20191245A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim | |
NI201600166A (es) | Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer | |
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
CO2018004933A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
AR087052A1 (es) | Derivados de amina ciclica como antagonistas del receptor ep4 | |
NI201300103A (es) | INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [ 2, 3-d] PIRIMIDINA TROPOMIOSINA | |
CL2015002520A1 (es) | Compuestos novedosos de pirimidina y piridina y su uso. | |
PE20150754A1 (es) | Derivados de azaindol que actuan como inhibidores de pi 3k | |
CL2022000032A1 (es) | Derivados de imidazo[4,5-c]piridina como agonistas de los receptores tipo toll | |
ECSP22022322A (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
PE20191490A1 (es) | DERIVADOS DE LA PIRIMIDIN ENONA TRICICLICA PARA LA INHIBICION DE RORy Y OTROS USOS | |
DOP2017000297A (es) | Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa | |
PE20191486A1 (es) | COMPUESTOS DE TIPO IMIDAZO[4,5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CANCER | |
ECSP22027784A (es) | Derivados de 2azaespiro[3.4]octano como agonistas de m4 | |
AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
PE20161177A1 (es) | Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2 | |
UY38906A (es) | Compuestos 2- derivados de azaspiro[3,4]octano como agonistas de m4 y composiciones de los mismos | |
AR086004A1 (es) | Formulaciones entericas de moduladores del receptor de glutamato metabotropico, proceso, uso | |
UY37084A (es) | Derivados de indano y su uso en terapias | |
AR125978A2 (es) | Compuestos, composiciones y métodos | |
CO2024000083A2 (es) | Pirrolo[2,3-d]pirimidinas sustituidas, su preparación y su aplicación terapéutica |